Toll-like receptor and its roles in myocardial ischemic/reperfusion injury

Medical Science Monitor

Volumn 17, Issue 4, 2011, Pages 100-109

  Fang, Yu ^a   Hu, Jianguo ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cardiomyocytes; Inflammatory cytokines; Innate immune; Ischemic reperfusion (I R); Toll like receptors (TLRs)

Indexed keywords

CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR;

ARTICLE; CYTOTOXICITY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; LOSS OF FUNCTION MUTATION; NONHUMAN; PROTEIN EXPRESSION; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

EID: 79953716236     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/msm.881709     Document Type: Article

References (134)

1. Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature, 2007; 449(7164): 819-26
2. Ishii KJ, Koyama S, Nakagawa A et al: Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe, 2008; 3(6): 352-63
3. Steinman RM, Banchereau J: Taking dendritic cells into medicine. Nature, 2007; 449(7161): 419-26
4. Steinman RM: Dendritic cells in vivo: a key target for a new vaccine science. Immunity, 2008; 29(3): 319-24
5. Janeway CA Jr: Approaching the asymptote? Evolution and revolution in immunology, Cold Spring Harb Symp Quant Biol, 1989; 54 Pt 1: 1-13
6. Kanzler H, Barrat FJ, Hessel EM, Coffman RL: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med, 2007; 13(5): 552-59
7. Leaver SK, Finney SJ, Burke-Gaffney A, Evans TW: Sepsis since the discovery of Toll-like receptors: disease concepts and therapeutic opportunities. Crit Care Med, 2007; 35(5): 1404-10
8. Zuany-Amorim C, Hastewell J, Walker C: Toll-like receptors as potential therapeutic targets for multiple diseases. Nat Rev Drug Discov, 2002; 1(10): 797-807
9. Mollen KP, Anand RJ, Tsung A et al: Emerging paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock, 2006; 26(5): 430-37
10. Jiang D, Liang J, Fan J et al: Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med, 2005; 11(11): 1173-79
11. Prince JM, Levy RM, Yang R et al: Toll-like receptor-4 signaling mediates hepatic injury and systemic inflammation in hemorrhagic shock. J Am Coll Surg, 2006; 202(3): 407-17
12. Lehnardt S, Lehmann S, Kaul D et al: Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol, 2007; 190(1-2): 28-33
13. Foot DK, Lewis RP, Pearson TA, Beller GA: Demographics and cardiology, 1950-2050. J Am Coll Cardiol, 2000; 35(5 Suppl. B): 66B-80B
14. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet, 1997; 349(9064): 1498-504
15. Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 2006; 3(11): e442
16. Tissier R, Berdeaux A, Ghaleh B et al: Making the heart resistant to infarction: how can we further decrease infarct size? Front Biosci, 2008; 13: 284-301
17. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell, 2006; 124(4): 783-801
18. Monie TP, Moncrieffe MC, Gay NJ: Structure and regulation of cytoplasmic adapter proteins involved in innate immune signaling. Immunol Rev, 2009; 227(1): 161-75
19. Matsushima N, Tanaka T, Enkhbayar P et al: Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors. BMC Genomics, 2007; 8: 124
20. Bella J, Hindle KL, McEwan PA, Lovell SC: The leucine-rich repeat structure. Cell Mol Life Sci, 2008; 65(15): 2307-33
21. Bell JK, Mullen GE, Leifer CA et al: Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol, 2003; 24(10): 528-33
22. Kajava AV, Vassart G, Wodak SJ: Modeling of the three-dimensional structure of proteins with the typical leucine-rich repeats. Structure, 1995; 3(9): 867-77
23. Kobe B, Deisenhofer J: A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature, 1995; 374(6518): 183-86
24. Choe J, Kelker MS, Wilson IA: Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science, 2005; 309(5734): 581-85
25. Jiang Z, Georgel P, Li C et al: Details of Toll-like receptor: adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci USA, 2006; 103(29): 10961-66
26. Nishiya T, DeFranco AL: ligand-dependent Toll-like receptor 4 (TLR 4)-oligomerization is directly linked with TLR 4-signaling. J Endotoxin Res, 2004; 10(4): 257-260
27. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins linking innate and acquired immunity, Nat Immunol, 2001; 2(8): 675-80
28. Medzhitov R, Janeway C Jr: Innate immune recognition: mechanisms and pathways. Immunol Rev, 2000; 173: 89-97
29. Pulendran B, Ahmed R: Translating innate immunity into immunological memory: implications for vaccine development, Cell, 2006; 124(4): 849-63
30. Trinchieri G, Sher A: Cooperation of Toll-like receptor signals in innate immune defence, Nat Rev Immunol, 2007; 7(3): 179-90
31. Lee MS, Kim YJ: Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem, 2007; 76: 447-80
32. Beutler B: Inferences, questions and possibilities in Toll-like receptor signalling. Nature, 2004; 430(6996): 257-63
33. Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol, 2007; 19(1): 3-10
34. Kawai T, Akira S: The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol, 2009; 21(4): 317-37
35. Kumar H, Kawai T, Akira S: Pathogen recognition in the innate immune response. Biochem J, 2009; 420(1): 1-16
36. Hoebe K, Du X, Georgel P et al: Identification of Lps2 as a key transducer of MyD88-independent TIR signaling. Nature, 2003; 424(6950): 743-48
37. Beutler B: Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol, 2000; 12(1): 20-26
38. Aliprantis AO, Yang RB, Mark MR et al: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science. 1999; 285(5428): 736-39
39. Lien E, Sellati TJ, Yoshimura A et al: Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J Biol Chem, 1999; 274(47): 33419-25
40. Hirschfeld M, Kirschning CJ, Schwandner R et al: Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol, 1999; 163(5): 2382-86
41. Farhat K, Riekenberg S, Heine H et al: Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol, 2008; 83(3): 692-701
42. Hayashi F, Smith KD, Ozinsky A et al: The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature, 2001; 410(6832): 1099-103
43. Mancuso G, Gambuzza M, Midiri A et al: Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol, 2009; 10(6): 587-94
44. Dennis VA, Dixit S, O'Brien SM et al: Live Borrelia burgdorferi spirochetes elicit inflammatory mediators from human monocytes via the Toll-like receptor signaling pathway. Infect Immun, 2009; 77(3): 1238-45
45. Murawski MR, Bowen GN, Cerny AM et al: Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol, 2009; 83(3): 1492-500
46. McCluskie MJ, Krieg AM: Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol, 2006; 311: 155-78
47. Yarovinsky F, Zhang D, Andersen JF et al: TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science, 2005; 308(5728): 1626-29
48. Beutler BA: TLRs and innate immunity. Blood, 2009; 113(7): 1399-407
49. O'Neill LA, Bowie AG: The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling. Nat Rev Immunol, 2007; 7(5): 353-64
50. Fitzgerald KA, Palsson-McDermott EM, Bowie AG et al: Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature, 2001; 413(6851): 78-83
51. Jiang Z, Georgel P, Li C et al: Details of Toll-like receptor: adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci USA, 2006; 103(29): 10961-66
52. Li C, Zienkiewicz J, Hawiger J: Interactive sites in the MyD88 Toll/interleukin (IL) 1 receptor domain responsible for coupling to the IL1beta signaling pathway. Biol Chem, 2005; 280(28): 26152-59
53. Janssens S, Beyaert R: A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci, 2002; 27(9): 474-82
54. Muzio M, Ni J, Feng P, Dixit VM: IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science, 1997; 278(5343): 1612-15
55. Medzhitov R, Preston-Hurlburt P, Kopp E et al: MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell, 1998; 2(2): 253-58
56. Yamamoto M, Sato S, Hemmi H et al: Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science, 2003; 301(5633): 640-43
57. Janssens S, Beyaert R: Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell, 2003; 11(2): 293-302
58. Li S, Strelow A, Fontana EJ, Wesche H: IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci USA, 2002; 99(8): 5567-72
59. Beutler B: Inferences, questions and possibilities in Toll-like receptor signaling. Nature, 2004; 430(6996): 257-63
60. Yamamoto M, Akira S: TIR domain-containing adaptors regulate TLRmediated signaling pathways. Nippon Rinsho, 2004; 62(12): 2197-203
61. Fitzgerald KA, McWhirter SM, Faia KL et al: IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol, 2003; 4(5): 491-96
62. Jennings RB, Sommers HM, Smyth GA et al: Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol, 1960; 70: 68-78
63. Yellon DM, Baxter GF: Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? Heart, 2000; 83(4): 381-87
64. Pierce GN, Czubryt MP: The contribution of ionic imbalance to ischemia/ reperfusion-induced injury. J Mol Cell Cardiol, 1995; 27(1): 53-63
65. Piper HM, García-Dorado D, Ovize M: A fresh look at reperfusion injury. Cardiovasc Res, 1998; 38(2): 291-300
66. Heyndrickx GR: Early reperfusion phenomena. Semin Cardiothorac Vasc Anesth, 2006; 10(3): 236-41
67. Kloner RA, Jennings RB: Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1. Circulation, 2001; 104(24): 2981-89
68. Wan S, LeClerc JL, Vincent JL: Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest, 1997; 112(3): 676-92
69. Li YJ, Ding WH, Gao W et al: Relation between inflammation related cytokines and myocardial microcirculatory reperfusion stateZhonghua Nei Ke Za Zhi, 2004; 43(2): 102-5
70. Atar D, Huber K, Rupprecht HJ et al: Rationale and design of the 'F.I.R.E.' study. A multicenter, double-blind, randomized, placebo-controlled study to measure the effect of FX06 (a fibrin-derived peptide Bbeta(15-42) on ischemia-reperfusion injury in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Cardiology, 2007; 108(2): 117-23
71. Vinten-Johansen J: Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res, 2004; 61(3): 481-97
72. Braunwald E, Kloner RA: The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation, 1982; 66(6): 1146-49
73. Kloner RA, Arimie RB, Kay GL et al: Evidence for stunned myocardium in humans: a 2001 update. Coron Artery Dis, 2001; 12(5): 349-56
74. Ambrosio G, Tritto I: Clinical manifestations of myocardial stunning. Coron Artery Dis, 2001; 12(5): 357-61
75. Kloner RA, Jennings RB: Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation, 2001; 104(25): 3158-67
76. Krug A, Du Mesnil de Rochemont, Korb G: Blood supply of the myocardium after temporary coronary occlusion. Circ Res, 1966; 19(1): 57-62
77. Boyle EM Jr, Pohlman TH, Cornejo CJ, Verrier ED: Endothelial cell injury in cardiovascular surgery: ischemia-reperfusionAnn Thorac Surg, 1996; 62(6): 1868-75
78. Ito H: No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med, 2006; 3(9): 499-506
79. Granger DN: Ischemia-reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation, 1999; 6(3): 167-78
80. Manning AS, Hearse DJ: Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol, 1984; 16(6): 497-518
81. Kaczorowski DJ, Tsung A, Billiar TR: Innate immune mechanisms in ischemia/reperfusion. Front Biosci (Elite Ed), 2009; 1: 91-98
82. Kaczorowski DJ, Nakao A, Vallabhaneni R et al: Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation, 2009; 87(10): 1455-63
83. Ao L, Zou N, Cleveland JC Jr et al: Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol, 2009; 297(1): H21-28
84. Zou N, Ao L, Cleveland JC Jr et al: Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion. Am J Physiol Heart Circ Physiol, 2008; 294(6): H2805-13
85. Yang J, Yang J, Ding JW et al: Myocardial toll like receptor 4 expression in a rat model of myocardial ischemia reperfusion injury. Zhonghua Xin Xue Guan Bing Za Zhi, 2008; 36(1): 57-61
86. Yang J, Yang J, Ding JW et al: Sequential expression of TLR4 and its effects on the myocardium of rats with myocardial ischemia-reperfusion injury. Inflammation, 2008; 31(5): 304-12
87. Cha J, Wang Z, Ao L et al: Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg, 2008; 85(5): 1678-85
88. Kaczorowski DJ, Nakao A, Mollen KP et al: Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion. Transplantation, 2007; 84(10): 1279-87
89. Dinerman JL, Mehta JL, Saldeen TG et al: Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol, 1990; 15(7): 1559-63
90. Engler RL, Dahlgren MD, Morris DD et al: Role of leukocytes in response to acute myocardial ischemia and reflow in dogs. Am J Physiol, 1986; 251(2 Pt 2): H314-23
91. Engler RL, Dahlgren MD, Peterson MA et al: Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia. Am J Physiol, 1986; 251(1 Pt 2): H93-100
92. Engler RL, Schmid-Schönbein GW, Pavelec RS: Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol, 1983; 111(1): 98-111
93. Jolly SR, Kane WJ, Hook BG et al: Reduction of myocardial infarct size by neutrophil depletion: effect of duration of occlusion. Am Heart J, 1986; 112(4): 682-90
94. Tracey KJ, Beutler B, Lowry SF et al: Shock and tissue injury induced by recombinant human cachectin. Science, 1986; 234(4775): 470-74
95. Finkel MS, Oddis CV, Jacob TD et al: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science, 1992; 257(5068): 387-89
96. Murray DR, Freeman GL: Tumor necrosis factor-alpha induces a biphasic effect on myocardial contractility in conscious dogs. Circ Res, 1996; 78(1): 154-60
97. Cain BS, Meldrum DR, Dinarello CA et al: Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med, 1999; 27(7): 1309-18
98. Cain BS, Meldrum DR, Harken AH, McIntyre RC Jr: The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg, 1998; 186(3): 337-50
99. Hennein HA, Ebba H, Rodriguez JL et al: Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg, 1994; 108(4): 626-35
100. te Velthuis H, Jansen PG, Oudemans-van Straaten HM et al: Myocardial performance in elderly patients after cardiopulmonary bypass is suppressed by tumor necrosis factor. J Thorac Cardiovasc Surg, 1995; 110(6): 1663-69
101. Menasché P, Haydar S, Peynet J et al: A potential mechanism of vasodilation after warm heart surgery. The temperature-dependent release of cytokines. Thorac Cardiovasc Surg, 1994; 107(1): 293-99
102. Meldrum DR, Dinarello CA, Shames BD et al: Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production. Potential ultimate effector mechanism of preconditioning. Circulation, 1998; 98(19 Suppl): II214-18; discussion II218-19
103. Oral H, Kapadia S, Nakano M et al: Tumor necrosis factor-alpha and the failing human heart. Clin Cardiol, 1995; 18(9 Suppl.4): IV20-27
104. Müller-Werdan U, Schumann H, Loppnow H et al: Endotoxin and tumor necrosis factor alpha exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J Mol Cell Cardiol, 1998; 30(5): 1027-36
105. Fahey TJ III, Yoshioka T, Shires GT, Fantini GA: The role of tumor necrosis factor and nitric oxide in the acute cardiovascular response to endotoxin. 1996; 223(1): 63-69
106. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol, 1998; 274(3 Pt 2): R577-95
107. Wan S, LeClerc JL, Vincent JL: Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation. Ann Thorac Surg, 1997; 63(1): 269-76
108. Maekawa N, Wada H, Kanda T et al: Improved myocardial ischemia/ reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol, 2002; 39(7): 1229-35
109. Krown KA, Page MT, Nguyen C et al: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest, 1996; 98(12): 2854-65
110. Vandenabeele P, Declercq W, Vanhaesebroeck B et al: NF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol, 1995; 154(6): 2904-13
111. Evans HG, Lewis MJ, Shah AM: Interleukin-1 beta modulates myocardial contraction via dexamethasone sensitive production of nitric oxide. Cardiovasc Res, 1993; 27(8): 1486-90
112. Oyama J, Shimokawa H, Momii H et al: Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest, 1998; 101(10): 2207-14
113. Guillén I, Blanes M, Gómez-Lechón MJ, Castell JV: Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. Am J Physiol, 1995; 269(2 Pt 2): R229-35
114. LaPointe MC, Isenović E: Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension, 1999; 33(1 Pt 2): 276-82
115. Schulz R, Nava E, Moncada S: Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol, 1992; 105(3): 575-80
116. Pinsky DJ, Cai B, Yang X et al: The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest, 1995; 95(2): 677-85
117. McTiernan CF, Lemster BH, Frye C et al: Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res, 1997; 81(4): 493-503
118. Deng MC, Dasch B, Erren M et al: Impact of left ventricular dysfunction on cytokines, hemodynamics, and outcome in bypass grafting. Ann Thorac Surg, 1996; 62(1): 184-90
119. Hofmann U, Domeier E, Frantz S et al: Increased myocardial oxygen consumption by TNF-alpha is mediated by a sphingosine signaling pathway. Am J Physiol Heart Circ Physiol, 2003; 284(6): H2100-5
120. Finkel MS, Hoffman RA, Shen L et al: Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol, 1993; 71(13): 1231-32
121. Kinugawa K, Takahashi T, Kohmoto O et al: Nitric oxide-mediated effects of interleukin-6 on [Ca2+]i and cell contraction in cultured chick ventricular myocytes. Circ Res, 1994; 75(2): 285-95
122. Gwechenberger M, Mendoza LH, Youker KA et al: Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation, 1999; 99(4): 546-51
123. Kukielka GL, Smith CW, Manning AM et al: Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation, 1995; 92(7): 1866-75
124. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res, 2001; 89(9): 763-71
125. Panichi V, Migliori M, De Pietro S et al: The link of biocompatibility to cytokine production. Kidney Int Suppl, 2000; 76: S96-103
126. Springer TA: Adhesion receptors of the immune system. Nature, 1990; 346(6283): 425-34
127. Entman ML, Youker K, Shoji T et al: Neutrophil induced oxidative injury of cardiac myocytes. A compartmented system requiring CD11b/ CD18-ICAM-1 adherence. J Clin Invest, 1992; 90(4): 1335-45
128. Appleyard RF, Cohn LH: Myocardial stunning and reperfusion injury in cardiac surgery. J Card Surg, 1993; 8(2 Suppl.): 316-24
129. Siminiak T, Smielecki J, Dye JF et al: Increased release of the soluble form of the adhesion molecules L-selectin and ICAM-1 but not E-selectin during attacks of angina pectoris. Heart Vessels, 1998; 13(4): 189-94
130. Yang J, Jiang H, Yang J et al: Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kB signaling pathway. Mol Cell Biochem, 2009; 330(1-2): 39-46
131. Baumgarten G, Knuefermann P, Schuhmacher G et al: Toll-like receptor 4, nitric oxide, and myocardial depression in endotoxemia. Shock, 2006; 25(1): 43-49
132. Zhao P, Wang J, He L et al: Deficiency in TLR4 signal transduction ameliorates cardiac injury and cardiomyocyte contractile dysfunction during ischemia. J Cell Mol Med, 2009; 13(8A): 1513-25
133. Hua F, Ha T, Ma J et al: Protection against myocardial ischemia/reperfusion injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism. J Immunol, 2007; 178(11): 7317-24
134. Riad A, Jäger S, Sobirey M et al: Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol, 2008; 180(10): 6954-61